A one-time treatment targets a lifelong problem
Researchers in London have reported early results from a clinical trial of VERVE-102, a gene-editing therapy designed to lower low-density lipoprotein cholesterol, or LDL cholesterol, after a single infusion. In the small Phase 1b study, the treatment reduced LDL cholesterol by as much as 62% at the highest dose level.
The work involved clinicians and scientists from University College London, University College London Hospitals and Barts Health NHS Trust, and the results were published in the New England Journal of Medicine. The trial focused on adults with heterozygous familial hypercholesterolemia, an inherited form of very high cholesterol, or with premature coronary artery disease.
Why the approach matters
High LDL cholesterol is a major long-term driver of cardiovascular disease, including heart attacks and strokes. Existing therapies can be effective, but they depend on regular use. Statins and other cholesterol-lowering medicines must often be taken daily or delivered through repeated injections over many years. The source text notes that adherence is a significant problem, with many patients discontinuing medication within a year.
VERVE-102 is being developed as a different kind of intervention. Instead of asking patients to keep taking medicine indefinitely, it aims to make a one-time edit that changes how the liver handles cholesterol. The therapy switches off the gene that directs the liver to make PCSK9, a protein that interferes with the body’s ability to clear LDL cholesterol from the bloodstream.
The idea is based on a natural model already seen in some people. Individuals born with inactive versions of the relevant PCSK9 pathway tend to have very low cholesterol levels and a substantially lower risk of heart disease across their lives. VERVE-102 is intended to reproduce that protective effect therapeutically.
What the trial showed
The early-stage study enrolled 35 adults. Its primary purpose was to assess safety, not to prove long-term clinical benefit. Even so, the cholesterol reductions reported from the highest dose group are notable because they suggest the therapy can produce the biological effect it was designed to achieve.
That matters for two reasons. First, it offers an early signal that single-dose gene editing for chronic cardiometabolic disease may be feasible. Second, it shifts gene editing farther beyond rare disease applications and into a much larger public-health category.
This remains an early trial, and the source material does not present the treatment as a replacement for standard care at this stage. Questions still include durability, broader safety across larger populations, how different patient groups respond, and whether LDL lowering from a single intervention will translate into fewer cardiovascular events over time.
From rare use case to mainstream prevention?
If later trials confirm the results, the broader significance could be considerable. Cholesterol management is one of the most common long-term medical tasks in modern health care. A therapy that can safely reduce LDL cholesterol after one infusion would challenge the current model of chronic treatment adherence and follow-up.
That does not mean conventional medicines disappear. More likely, a successful one-time therapy would first be aimed at patients with inherited risk, poor tolerance to existing drugs, or severe early-onset disease. But the strategic implication is larger: gene editing is increasingly being tested not only as a rescue technology for rare genetic disorders, but also as a platform for common diseases that affect millions.
For now, the study is best read as a strong early signal rather than a finished answer. The data show that one-time LDL reduction through targeted gene editing is moving from theory into human testing, and that the first clinical readout is substantial enough to justify close attention.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
